Freyja Jónsdóttir

Freyja Jónsdóttir

Auto-generated profile, based on publicly available information

Freyja Jónsdóttir

Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
AWAnita Elaine Weidmann
Anita Elaine Weidmann
GPGuðný Björk Proppé
Guðný Björk Proppé
RMRut Matthíasdóttir
Rut Matthíasdóttir
ITIvana TADIĆ
Ivana TADIĆ
PGPétur Sigurdur Gunnarsson
Pétur Sigurdur Gunnarsson
FJFreyja Jónsdóttir
Freyja Jónsdóttir
Background: While medication is a recognized risk factor of delirium, there is currently a lack of detailed information on managing and preventing medication-induced cases. Aim: This review summarizes the information provided in neurology guidelines on medication-induced delirium in patients with and without dementia to inform guidance on prevention and management strategies. Method: A systematic literature review was conducted across 114 neurological and medical organisations, Guideline Central and PubMed. Guidelines, consensus guidelines, white papers, frameworks, protocols, standard procedures, action plans and strategic documents detailing the prevention and management of medication-induced delirium in adults with or without dementia were included. Title and full-text screening was completed independently by two reviewers using PICOS. AGREE II was used to assess reporting quality. A data extraction tool was designed based on the Cochrane Effective Practice and Organization of Care Review Group (EPOC) checklist and a mixed methods approach to synthesis adopted. The systematic review protocol was registered with International Prospective Register of Systematic Reviews (PROSPERO) [ID: CRD42022366025]. Results: Out of 143 guidelines identified, 30 were included. Information for 140 individual medications was extracted. Medications most frequently cited included sedatives (n = 24/80%), opioids (n = 22/73,3%), psychoactive drugs (n = 21/70%) + anti-convulsants (n = 14/46,7%), anti-cholinergic agents (n = 20/66,7%), antihistamines (n = 18/60%), and steroids (n = 16/53,3%). Despite a consistently high-quality rating (n = 19, 63,3%), the detail provided often lacks specificity about pharmacological mechanisms, individual risk, dosing instructions, associated symptoms, therapeutic alternatives and avoidable drug-drug combinations. In relation to dementia, detailed information on the use of antipsychotics, cholinesterase inhibitors and benzodiazepines was extracted. No papers were excluded based on their quality. Conclusion: No single guideline contains enough information on the risk, prevention, and management of medication-induced delirium to sufficiently support clinical decision making.

5 May 2023 in BJS Open
Verified
Journal Article
Open access
PDF file
FJFreyja Jónsdóttir
Freyja Jónsdóttir
ABAnna B Blöndal
Anna B Blöndal
AGAðalsteinn Guðmundsson
Aðalsteinn Guðmundsson
IBIan Bates
Ian Bates
JSJennifer M Stevenson
Jennifer M Stevenson
MSMartin I Sigurðsson
Martin I Sigurðsson
The aim of this study was to determine the prevalence of preoperative polypharmacy and the incidence of postoperative polypharmacy/hyper-polypharmacy in surgical patients and their association with adverse outcomes. This was a retrospective, population-based cohort study among patients older than or equal to 18 years undergoing surgery at a university hospital between 2005 and 2018. Patients were categorized based on the number of medications: non-polypharmacy (fewer than 5); polypharmacy (5–9); and hyper-polypharmacy (greater than or equal to 10). The 30-day mortality, prolonged hospitalization (greater than or equal to 10 days), and incidence of readmission were compared between medication-use categories. Among 55 997 patients, the prevalence of preoperative polypharmacy was 32.3 per cent (95 per cent c.i. 33.5 to 34.3) and the prevalence of hyper-polypharmacy was 25.5 per cent (95 per cent c.i. 25.2 to 25.9). Thirty-day mortality was higher for patients exposed to preoperative hyper-polypharmacy (2.3 per cent) and preoperative polypharmacy (0.8 per cent) compared with those exposed to non-polypharmacy (0.6 per cent) (P < 0.001). The hazards ratio (HR) of long-term mortality was higher for patients exposed to hyper-polypharmacy (HR 1.32 (95 per cent c.i. 1.25 to 1.40)) and polypharmacy (HR 1.07 (95 per cent c.i. 1.01 to 1.14)) after adjustment for patient and procedural variables. The incidence of longer hospitalization (greater than or equal to 10 days) was higher for hyper-polypharmacy (11.3 per cent) and polypharmacy (6.3 per cent) compared with non-polypharmacy (4.1 per cent) (P < 0.001). The 30-day incidence of readmission was higher for patients exposed to hyper-polypharmacy (10.2 per cent) compared with polypharmacy (6.1 per cent) and non-polypharmacy (4.8 per cent) (P < 0.001). Among patients not exposed to polypharmacy, the incidence of new postoperative polypharmacy/hyper-polypharmacy was 33.4 per cent (95 per cent c.i. 32.8 to 34.1), and, for patients exposed to preoperative polypharmacy, the incidence of postoperative hyper-polypharmacy was 16.3 per cent (95 per cent c.i. 16.0 to 16.7). Preoperative polypharmacy and new postoperative polypharmacy/hyper-polypharmacy are common and associated with adverse outcomes. This highlights the need for increased emphasis on optimizing medication usage throughout the perioperative interval. NCT04805151 (http://clinicaltrials.gov).

28 March 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
FJFreyja Jonsdottir
Freyja Jonsdottir
ABAnna B Blondal
Anna B Blondal
AGAdalsteinn Gudmundsson
Adalsteinn Gudmundsson
IBIan Bates
Ian Bates
JSJennifer Mary Stevenson
Jennifer Mary Stevenson
MSMartin I Sigurdsson
Martin I Sigurdsson
Objectives To determine the prevalence and incidence of polypharmacy/hyperpolypharmacy and which medications are most prescribed to patients with varying burden of polypharmacy. Design Retrospective, population-based cohort study. Setting Iceland. Participants Including patients (≥18 years) admitted to internal medicine services at Landspitali – The National University Hospital of Iceland, between 1 January 2010 with a follow-up of clinical outcomes through 17 March 2022. Main outcomes measures Participants were categorised into medication use categories of non-polypharmacy (10) based on the number of medications filled in the year predischarge and postdischarge. The primary outcome was prevalence and incidence of new polypharmacy. Secondary outcomes were mortality, length of hospital stay and re-admission. Results Among 85 942 admissions (51% male), the median (IQR) age was 73 (60–83) years. The prevalence of preadmission non-polypharmacy was 15.1% (95% CI 14.9 to 15.3), polypharmacy was 22.9% (95% CI 22.6 to 23.2) and hyperpolypharmacy was 62.5% (95% CI 62.2 to 62.9). The incidence of new postdischarge polypharmacy was 33.4% (95% CI 32.9 to 33.9), and for hyperpolypharmacy was 28.9% (95% CI 28.3 to 29.5) for patients with preadmission polypharmacy. Patients with a higher level of medication use were more likely to use multidose drug dispensing and have a diagnosis of adverse drug reaction. Other comorbidities, including responsible subspeciality and estimates of comorbidity and frailty burden, were identical between groups of varying polypharmacy. There was no difference in length of stay, re-admission rate and mortality. Conclusions Preadmission polypharmacy/hyperpolypharmacy and postdischarge new polypharmacy/hyperpolypharmacy is common amongst patients admitted to internal medicine. A higher level of medication use category was not found to be associated with demographic, comorbidity and clinical outcomes. Medications that are frequently inappropriately prescribed were among the most prescribed medications in the group. An increased focus on optimising medication usage is needed after hospital admission. Trial registration number NCT05756400.

8 February 2023 in Surgery
Verified
Journal Article
Closed access
ÞAÞorsteinn Ívar Albertsson
Þorsteinn Ívar Albertsson
FJFreyja Jónsdóttir
Freyja Jónsdóttir
SKSigurbergur Karason
Sigurbergur Karason
MSMartin I. Sigurdsson
Martin I. Sigurdsson

3 February 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
LHLeon Arnar Heitmann
Leon Arnar Heitmann
IGIngibjorg Jona Gudmundsdottir
Ingibjorg Jona Gudmundsdottir
FJFreyja Jonsdottir
Freyja Jonsdottir
TGTomas Gudbjartsson
Tomas Gudbjartsson
MSMartin Ingi Sigurdsson
Martin Ingi Sigurdsson
We assessed adherence to statins, beta-blockers and renin–angiotensin system (RAS) inhibitors after coronary artery bypass graft surgery and factors associated with non-adherence. This nationwide retrospective cohort study included all individuals undergoing coronary artery bypass surgery from 22 May 2007 to 20 December 2018, at Landspitali—the National University Hospital (n = 1536). Data on dispensed prescriptions were retrieved from the National Prescription Medicine Registry. Adherence was estimated by the proportion of days covered up to 2 years after hospital discharge, with cut-offs for strict adherence and non-adherence at over 80% and under 50%, respectively. Multivariable logistic regression was used to assess variables associated with non-adherence. Criteria for strict adherence were met by 39.2%, 36.9% and 30.1% of patients for statins, beta-blockers and RAS inhibitors, respectively. Non-adherence criteria were met for 14.4%, 25.9% and 43.6% of patients for statins, beta-blockers and RAS inhibitors, respectively. High Hospital Frailty Risk Score Class (statins: odds ratio (OR) 2.29, confidence interval (CI) 1.02–4.86; RAS inhibitors: OR 2.06, CI 1.04–4.04), concomitant aortic valve replacement (statins: OR 1.64, CI 1.11–2.38; RAS inhibitors: OR 1.78, CI 1.26–2.52) and a new prescription for a medication class following surgery (statins: OR 2.87, CI 2.06–4.01; beta-blockers: OR 1.70, CI 1.32–2.18; RAS inhibitors: OR 6.95, CI 5.27–9.25) were associated with non-adherence. Non-adherence to medical therapy after coronary artery bypass surgery is common. Patients with a higher burden of frailty and patients naive to the medical treatment of coronary artery disease should be a target group for efforts to increase medication adherence.

31 July 2024 in The American Journal of Medicine
Verified
Journal Article
Closed access
FJFreyja Jónsdóttir
Freyja Jónsdóttir
ABAnna B. Blöndal
Anna B. Blöndal
AGAðalsteinn Guðmundsson
Aðalsteinn Guðmundsson
IBIan Bates
Ian Bates
JSJennifer M. Stevenson
Jennifer M. Stevenson
MSMartin I. Sigurðsson
Martin I. Sigurðsson